Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RN7SL51P is a genomic segment categorized as a pseudogene, sharing high sequence similarity with the functional 7SL RNA gene but lacking protein-coding capacity and biological function[1][6][7]. The canonical 7SL RNA is a conserved element of the signal recognition particle (SRP), which plays a central role in the co-translational targeting of proteins to the endoplasmic reticulum in eukaryotic cells[3][5]. Unlike functional 7SL RNA, pseudogenes such as RN7SL51P do not produce functional RNA molecules and are typically not expressed or translated; rather, they arise via gene duplication or retrotransposition, resulting in nonfunctional sequences[6][7]. Assessment of therapeutic target status and correctness: - RN7SL51P is *not* a therapeutic target, receptor, enzyme, transporter, or any other molecular entity with recognized druggable activity[1][6]. - The designation RN7SL51P is correct in terms of naming conventions for pseudogenes, but it is *not* a functional molecular target, so returning it as a therapeutic target would be incorrect. - There are no known biological functions, disease associations, interacting drugs, biomarker utility, or safety concerns directly attributed to RN7SL51P, in line with its status as a nonfunctional pseudogene[1][6][7]. If you seek information on the functional RNA molecule (7SL RNA, SRP RNA), refer to entries for "Signal recognition particle 7SL RNA," which is a key structural ribonucleoprotein in protein targeting, unlike pseudogene copies[3][5]. Summary: RN7SL51P is a pseudogene of 7SL RNA, with no protein product, biological function, or relevance as a therapeutic target[1][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, 7SL, cytoplasmic 51, pseudogene (RN7SL51P).